Holen Sie sich die Stockscreener-App
0.6603
6.61%
-0.0467
Schlusskurs vom Vortag:
$0.707
Offen:
$0.707
24-Stunden-Volumen:
300.17K
Relative Volume:
0.47
Marktkapitalisierung:
$21.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.23M
KGV:
-0.5119
EPS:
-1.2898
Netto-Cashflow:
$-41.53M
1W Leistung:
-8.34%
1M Leistung:
-8.77%
6M Leistung:
-84.46%
1J Leistung:
-72.77%
1-Tages-Spanne:
$0.6467
$0.707
1-Wochen-Bereich:
$0.61
$0.835
52-Wochen-Spanne:
$0.61
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Firmenname
Skye Bioscience Inc
Sektor
Branche
Telefon
(858) 410-0266
Adresse
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs GOODO, PSNYW, SHMD, DWLD, QQQE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.87 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
3.86 | 378.34M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
6.31 | 383.66M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
44.12 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.94 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-08-15 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-09-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy - MSN
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pio - GuruFocus
Citizens reiterates Skye Bioscience stock rating on weight loss data By Investing.com - Investing.com Canada
Skye Bioscience (SKYE) Advances Nimacimab Development with Promi - GuruFocus
SKYE: Additive weight loss and durable efficacy drive nimacimab's advancement as a GLP-1 add-on - TradingView
Earnings call transcript: Skye Bioscience Q4 2025 highlights clinical advancements - Investing.com
Skye (SKYE) Reinforces Nimacimab Strategy with Promising Data - GuruFocus
Q4 and full year results reveal momentum, Skye Bioscience, Inc. asserts - Traders Union
Skye Bioscience 2025 10-K: Net loss $(55.9M), Loss per share $(1.41) - TradingView
Skye obesity drug combo shows 22.3% loss, over 50% less regain - Stock Titan
A Peek at Skye Bioscience's Future Earnings - Benzinga
Growth Value: Will Skye Bioscience Inc benefit from government policyQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Market Recap: Can Skye Bioscience Inc weather a recessionEarnings Growth Summary & Risk Managed Investment Strategies - baoquankhu1.vn
Growth Report: What are the analyst revisions for Skye Bioscience IncIs KNSL stock a good investment in YEARVolume Spike & Low Volatility Stock Suggestions - baoquankhu1.vn
Does Skye Bioscience Inc have a competitive edgeJuly 2025 Catalysts & Low Drawdown Momentum Ideas - baoquankhu1.vn
Smart Money: Can Skye Bioscience Inc beat the S P 5002025 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Risk Report: Whats the outlook for Skye Bioscience Incs sectorJuly 2025 Closing Moves & Expert Curated Trade Ideas - baoquankhu1.vn
Skye Bioscience Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Aug Intraday: Is Skye Bioscience Inc in a bullish channelQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Breakout Zone: Will Skye Bioscience Inc outperform the market in YEARIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - Sahm
Why Did Skye Bioscience Stock Plummet A Whopping 60% Today? - Stocktwits
Skye Bioscience schedules March 2026 earnings release with Q4 and full-year results - Traders Union
Skye Bioscience to Release 2025 Financial Results and Business Update on March 10, 2026 - geneonline.com
Skye Bioscience Stock Quote, Share Price, News and Analysis - Longbridge
SKYE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Can Skye Bioscience Inc weather a recessionWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Volume Summary: Should I hold or sell FATBP nowJuly 2025 Drop Watch & Risk Managed Investment Signals - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
SKYE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SKYE Earnings History & Surprises | EPS & Revenue Results | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience says Kaitlyn Arsenault to step down as CFO effective Feb 20 - marketscreener.com
CFO exits Skye Bioscience (SKYE) with $450k severance; CEO takes accounting duties - Stock Titan
Skye Bioscience, Inc. Announces Chief Financial Officer Changes, Effective February 20, 2026 - marketscreener.com
2026-02-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-02-17 | Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-02-15 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
How do insiders feel about Skye Bioscience Inc.Dividend Hike & Weekly Breakout Opportunity Watchlist - mfd.ru
SKYE Should I Buy - Intellectia AI
What’s the outlook for Skye Bioscience Inc.’s sector2025 Trade Ideas & AI Forecasted Entry and Exit Points - mfd.ru
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
SKYE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Geopolitics Watch: Does Skye Bioscience Inc meet Warren Buffetts criteriaQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
A | Can Atmos Energy Corporation (AEO) stock retain market dominanceEarnings Overview Summary & Expert Curated Trade Setup Alerts - mfd.ru
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscience, Inc. (SKYE) And Encourages Shareholders to Connect | NDAQ:SKYE | Press Release - Stockhouse
Aug EndMonth: How does IHS Holding Limited compare to its peersJuly 2025 Institutional & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Can Skye Bioscience Inc. stock reach $100 price targetWeekly Trade Analysis & Technical Confirmation Trade Alerts - mfd.ru
Skye Bioscience (SKYE) director receives grant of 35,000 options - Stock Titan
Skye Bioscience (SKYE) grants CEO 280,000 stock options at $0.82 - Stock Titan
Finanzdaten der Skye Bioscience Inc-Aktie (SKYE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):